Evidence map›Paper›PMID 38908367›Full record

ArticleCell2024

TERT activation targets DNA methylation and multiple aging hallmarks.

Hong Seok Shim, Jonathan Iaconelli, Xiaoying Shang, Jiexi Li, Zheng D Lan, Shan Jiang, Kayla Nutsch, Brittney A Beyer, Luke L Lairson, Adam T Boutin and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. LiposomalInternational journal of molecular sciences · 2026
    Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Observational
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Telomerase mRNA-Lipid nanoparticles attenuate neuroinflammation after traumatic brain injury in mice.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  19. Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Hong Seok ShimDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jonathan IaconelliDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Xiaoying ShangDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jiexi LiDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Zheng D LanDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Shan JiangInstitute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Kayla NutschDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Brittney A BeyerDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Luke L LairsonDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Adam T BoutinDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Michael J BollongDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Peter G SchultzDepartment of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA.
Ronald A DePinhoDepartment of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: rdepinho@mdanderson.org.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
TELOMERASE IN DEVELOPMENT, SENESCENCE AND NEOPLASIAR01CA084628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2000 to 2019
$10.5M
Super-Resolution OMX MicroscropeS10RR029552 · NCRR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ZAL, TOMASZ · 2011 to 2011
$1.0M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA084628NCRR NIH HHS S10 RR029552
6 · The paper itself

Abstract

Insufficient telomerase activity, stemming from low telomerase reverse transcriptase (TERT) gene transcription, contributes to telomere dysfunction and aging pathologies. Besides its traditional function in telomere synthesis, TERT acts as a transcriptional co-regulator of genes pivotal in aging and age-associated diseases. Here, we report the identification of a TERT activator compound (TAC) that upregulates TERT transcription via the MEK/ERK/AP-1 cascade. In primary human cells and naturally aged mice, TAC-induced elevation of TERT levels promotes telomere synthesis, blunts tissue aging hallmarks with reduced cellular senescence and inflammatory cytokines, and silences p16

Indexed as

AgingDNA MethylationTelomeraseAnimalsBrainCellular SenescenceCyclin-Dependent Kinase Inhibitor p16DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3BHumansMaleMiceMice, Inbred C57BLNeurogenesisPromoter Regions, GeneticTelomereCyclin-Dependent Kinase Inhibitor p16DNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3BTelomeraseTERT protein, humanTert protein, mouseTranscription Factor AP-1adult neurogenesiscognitionepigeneticsinflammationp16(INK4a)senescencetelomerasetelomere

Identifiers

PMID38908367
PMCPMC11552617

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.